An Introduction to Pulmonary Hypertension
With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape
Our supporting partners do not constitute an endorsement of the content on this page.
Pulmonary Hypertension Content
Luis Jara Palomares, ERS 2019 – Environmental Factors in Pulmonary Embolism and PAH
Luis Jara-Palomares, from Seville, Spain, joins us at ERS 2019 in Madrid, to discuss the main findings from his study into the significance of environmental factors in pulmonary embolism and pulmonary arterial hypertension. Questions 1. What are the major causes of pulmonary embolism and pulmonary arterial hypertension? (0:06) 2. What is known about the impact […]
Sandeep Sahay, ATS 2019 – New World Symposium Proceedings on Pulmonary Hypertension
Sandeep Sahay (Houston Methodist Lung Center, Houston Methodist Hospital, Houston, TX, USA) speaks from the 2019 ATS conference in Dallas, TX, USA about portopulmonary hypertension, how it differs from other types of hypertension and changes to the diagnostic criteria. He also addresses the changes this will have on patients and addressing unmet needs in hypertension. […]
James R Klinger, CHEST 2018 – Management of pulmonary arterial hypertension
James R Klinger (Rhode Island Hospital, and Warren Alpert Medical School, Brown University, Providence, RI, US) chats to us on the topic of his session entitled: Current Quandaries in Pulmonary Arterial Hypertension (PAH) Management. Questions 1. What are the major challenges in the management of pulmonary arterial hypertension (PAH)? (0:10) 2. What have been the […]
Namita Sood, CHEST 2018 – Pulmonary arterial hypertension: diagnosis and current therapies
Namita Sood (University of Texas Health Science Center, Houston, TX, US) discusses challenges and advances in pulmonary arterial hypertension (PAH). Questions 1. What is the definition of pulmonary arterial hypertension (PAH)? (0:10) 2. What are the major challenges in the diagnosis of PAH? (0:43) 3. How is PAH classified and what are the most important […]
Pulmonary Arterial Hypertension Management – A New Approach For a Rare Disease
European Respiratory & Pulmonary Diseases, 2016;2(2):50–1 DOI: //doi.org/10.17925/ERPD.2016.02.02.50
Pulmonary arterial hypertension (PAH) is a rare, deadly and incurable condition.1 With a five-year survival rate below 60%, the outcome of this disease is not any better than that of many cancers.1,2 However, numerous treatment options are currently available: more than 20 randomised controlled trials (RCTs) have been conducted over the past 10 years, allowing […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!